Probiodrug AG celebrates its successful IPO on Euronext Amsterdam

Back

Market capitalization of € 102.4 million

Amsterdam – 27 October 2014 – Today Euronext welcomes Probiodrug AG, a biopharmaceutical company headquartered in Germany, on its regulated market in Amsterdam (ticker symbol: PBD, ISIN: DE0007921835).

Probiodrug AG is a biopharmaceutical company focusing on the research and development of new therapeutic products for the treatment of Alzheimer’s Disease. Probiodrug’s aim is to become a leading company in the development of Alzheimer’s Disease treatments and to thereby provide a better life for Alzheimer’s patients.

Probiodrug was listed through the admission to trading of 5,241,693 existing shares and 1,475,409 new public shares on Euronext Amsterdam. The admission and issue price of Probiodrug was set at € 15.25 per share. Market capitalisation was € 102.4 million on the day of listing. The offering raised € 22.5 million altogether.

Dr. Konrad Glund, Chief Executive Officer of Probiodrug said: “Probiodrug’s listing on Euronext is a very important landmark for the company as we look to develop innovative therapeutics to treat people with Alzheimer’s Disease. The €22.5 million fund raising will enable us to advance the clinical development of our lead product candidate PQ912 in early Alzheimer’s patients and support the further development of our other product candidates PBD-C06 and PQ1565.

Alzheimer’s Disease is a large underserved market open for new drug approaches. We believe our differentiated approach presents a significant opportunity for patients, and will also generate significant value for our shareholders. We would like to welcome our new investors and look forward on our progress as we continue to grow the company.

Jos Dijsselhof, acting CEO of Euronext Amsterdam said: “On Euronext, we have already a strong presence of life sciences companies and Probiodrug is a great addition to our market. This IPO and listing demonstrates the attractiveness of public equity markets as a source of financing for SME to help them achieve the next stage in their development.  Our EnterNext initiative in particular is designed to promote capital markets to SMEs and help them achieve access to the capital markets.

“We are delighted to welcome Probiodrug AG on Euronext Amsterdam. Capital markets funding will contribute to the company’s continued development of an innovative approach to treating Alzheimer’s.

Probiodrug AG’s choice of listing venue, reinforces Euronext’s position as the leading European stock exchange for life science companies, on which 36 IPOs, representing over 50% of all European life science IPOs, have been executed since 2010. The international IPOs of Mainstay Medical PLC and Probiodrug AG in 2014 demonstrate the attraction of Euronext to a broad set of life science issuers,” said Albert Ganyushin, Head of International Listings at Euronext.

To mark the listing, Dr. Konrad Glund, Chief Executive Officer of Probiodrug AG, sounded the gong in Amsterdam to open the financial market, accompanied by Probiodrug’s Management, Board Members, investors, advisers and the listing team of Euronext.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.